Remacemide.
Muir
K T
KT
Fisons Pharmaceuticals, Divisional Research and Development, Rochester, NY.
Palmer
G C
GC
D000081:Acetamides / Q000009:adverse effects / Q000493:pharmacokinetics / Q000627:therapeutic use*; D000818:Animals; D000927:Anticonvulsants / Q000009:adverse effects / Q000493:pharmacokinetics / Q000627:therapeutic use*; D001921:Brain / Q000187:drug effects; D015507:Drugs, Investigational / Q000009:adverse effects / Q000493:pharmacokinetics / Q000627:therapeutic use*; D004569:Electroencephalography / Q000187:drug effects; D004827:Epilepsy / Q000097:blood / Q000188:drug therapy*; D005071:Evoked Potentials / Q000187:drug effects; D006801:Humans; D051379:Mice; D051381:Rats
D000081:Acetamides; D000927:Anticonvulsants; D015507:Drugs, Investigational; C067553:remacemide